Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060936) titled 'Usefulness of GLP-1 receptor agonists in patients with type 2 diabetes who are receiving antipsychotic therapy and have obesity or fatty liver' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - Osaka Prefectural Hospital Organization Osaka Psychiatric Medical Center
Condition:
Condition - Patients with type 2 diabetes who are receiving antipsychotic therapy and have obesity or fatty liver
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - to clarify the usefulness of GLP-1 receptor agonists in patients with type 2 diabetes who are receiving antipsychotic medications and who also have obesity or fatty liver disease
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - (1) Patients with type 2 diabetes who are currently receiving antipsychotic medication and have not yet been treated with a GLP-1 receptor agonist
(2) BMI greater than 27 or diagnosis of fatty liver by imaging (ultrasound or CT)
Patients who meet both criteria (1) and (2) will begin treatment with a GLP-1 receptor agonist.
Key exclusion criteria - Inability to comply with GLP-1 receptor agonist therapy
Any other condition judged inappropriate by the attending physician
Target Size - 50
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 11 Month 07 Day
Date of IRB - 2025 Year 12 Month 08 Day
Anticipated trial start date - 2026 Year 01 Month 07 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069681
Disclaimer: Curated by HT Syndication.
